32 articles
Toremifene
Toremifene (Fareston) is a chlorinated tamoxifen analogue SERM approved in 1997 for ER-positive or unknown metastatic breast cancer in postmenopausal women; trials show efficacy equivalent to tamoxifen with a QT-prolongation boxed warning.
Vepdegestrant
Vepdegestrant (Veppanu, ARV-471, PF-07850327) is an oral PROTAC estrogen receptor alpha degrader, the first PROTAC approved (FDA, May 1, 2026), for ESR1-mutated ER-positive HER2-negative advanced breast cancer after endocrine therapy.